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A B S T R A C T   
A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid 
mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of 
care treatment following his own research and he was enrolled in a named patient programme of IMM-101. He 
was advised to correct his low vitamin D3 level and to start using anti-inflammatories such as aspirin, bromelain 
and low dose Naltrexone. At review one year later a CT scan showed no change and he continued on the regimen. 
Four years after the diagnosis a CT scan showed that there was a modest but definite progression of the left 
malignant pleural thickening, and a new right-sided effusion, enlargement of several intrathoracic nodes which 
had been noted on the early scans. The chest wall lump eventually broke down and required local radiotherapy. 
He then developed abdominal pain and found to have peritoneal disease. Last year he obtained the cannabinoids 
CBD and THC which slowed down the disease and a CT scan after he had been on this for six months, showed that 
his disease was fairly stable with marginal progression.   
1. Introduction 
Mesothelioma is accepted to arise as a direct consequence of asbestos 
exposure and this often occurs several decades prior to symptoms from 
the progressing tumour. 
Unlike several other cancer types, it does not respond well to 
chemotherapy and surgery is very rarely curative. In addition to 
chemotherapy being poorly effective in many cases of mesothelioma, it 
is also suspected of hastening the progression of the tumour in some 
circumstances, a feature which is seen with some immunotherapy 
treatments in a minority of patients. 
2. Case presentation 
A 64 year old male heating engineer was investigated for a persistent 
cough and found to have with a pleural effusion, pleural nodules and 
increased thoracic lymph nodes. Biopsy revealed an epithelioid meso-
thelioma (Fig. 1). He declined standard of care treatment following his 
own research into the very low likelihood of cure and the potential side- 
effects of both the surgery and chemotherapy. 
Following informed consent, he was enrolled on a named patient 
programme of IMM-101 and he was advised to correct his low vitamin 
D3 level and to start using anti-inflammatories, such as aspirin, 
bromelain and low dose Naltrexone (LDN). IMM-101 is a suspension of 
heat-killed whole cell Mycobacterium obuense, which enhances the innate 
immune response and dendritic cell maturation and which has been 
shown to induce clinical responses in melanoma patients [1] and to 
increase survival in a randomised study in pancreatic cancer [2]. 
Naltrexone has been found to be a strong antagonist of TLR9 which is 
commonly over-expressed in chronic inflammation and several tumour 
types [3]. IMM-101 was given intradermally in the deltoid area at reg-
ular intervals initially every months with no significant toxicities apart 
from a local reaction at the site of injection. 
At review one year later the CT scan showed no change and he 
continued on the regimen. At a review three years further on, his CT 
showed slow progression (Fig. 2a). Osteoporosis was also noted and he 
was started on Zoledronic acid which is of interest as it has innate im-
mune stimulatory properties enhancing gamma delta T-cell activity [4]. 
Four years after the diagnosis he presented with an enlarging chest 
wall lesion where the original biopsy had been performed (Fig. 2b). A CT 
scan showed that there was a modest but definite progression of the left 
malignant pleural thickening, and a new right-sided effusion with 
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peritoneal nodularity with enlargement of several intrathoracic nodes 
which had been noted on the early scans. 
The chest wall lump eventually broke down and responded to local 
radiotherapy. He then developed abdominal pain and was found to have 
peritoneal disease (Fig. 2c). 
Following radiotherapy to his chest wall disease he took no other 
treatment, apart from a cannabis oil preparation, which he felt improved 
his symptoms following radiotherapy. CT scans from baseline to 65 
months are shown (Fig. 2 a-c). 
3. Discussion 
The pathogenesis of mesothelioma is a very low grade chronic in-
flammatory reaction to the asbestos fibres, which over many years leads 
to collective mutations leading to the mesothelioma. 
The importance of chronic inflammation and cancer is well known 
[5] and the pathogenic association is that chronic inflammation sup-
presses cell mediated immunity and enhances angiogenic and tumour 
growth factors. In this environment, random mutations are much more 
likely to survive and progress than in non-inflamed environments. An 
example of this is the enhanced development of colon cancer in patients 
with ulcerative colitis. The chronic inflammation and reduce immune 
surveillance allow a mutated gene (eg ras) to survive and develop 
further mutations, aided by growth factors. 
On the basis of the known pathogenesis of mesothelioma we pro-
posed our immune-modulatory and anti-inflammatory based pro-
gramme. IMM-101 enhances the innate immune response as well as 
inhibiting Th-2 responses. LDN inhibits TLR-9 expression and inflam-
matory cytokines, such as IL-6. This would reduce the inflammation 
drive and enhance immunity and hence reduce the inflammatory driven 
progression of carcinogenesis. This case suggests that this approach 
should be trialled in similar cases of mesothelioma, particularly in the 
third of patients with mesothelioma who, like our patient, refuse stan-
dard surgery and chemotherapy options. 
The patient gave his full written consent for this report and is keen 
that others can benefit from this treatment. 
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Fig. 1. a) HE stained section showing an epithelioid mesothelioma: tumour comprised of polygonal epithelial-like cells in a tubulopapillary and acinar growth 
pattern. No sarcomatoid component seen; b) Strong and diffuse cytoplasmic and nuclear staining for Calretinin indicates mesothelial nature of cells; c) WT1 shows 
strong nuclear staining, confirming mesothelial cells. 
Fig. 2. a) Slow progression of pleural and pulmonary disease. A) Baseline CT demonstrates a small left sided pleural effusion with a subtle nodular pleural disease 
posteriorly (open arrow). A pulmonary metastasis in the right upper lobe (closed arrow) measures 10mm in maximal diameter at baseline. B, C & D) CT studies at 46 
months, 54 months and 65 months respectively post baseline demonstrating a slow interval progression. The pleural disease is circumferential but shows very little 
change from 46 to 65 months. The right lobe metastasis measures 13mm on all three studies. Fig. 2b) New site of disease developed during treatment in left chest wall 
at site of previous biopsy. A) No disease seen in left chest wall at baseline CT. B) 31 months CT study demonstrates subtle soft tissue nodule (closed arrow) in left chest 
wall but patient asymptomatic from this site. C) 50 months CT study demonstrates marked enlargement in the left chest wall mass (open arrow) which is infiltrative 
within the left serratus anterior muscle. The mass is now symptomatic with new chest wall pain attributed to this disease. D) 65 months CT study demonstrates slight 
reduction in bulk of left chest wall disease post-radiotherapy. Fig. 2c) New site of disease developed during treatment within the peritoneal cavity. a) No peritoneal 
disease at baseline. b) New subtle haziness of peritoneum (closed arrow) at 46 months. c) Progression of the peritoneal haziness in the right subphrenic space at 50 
months with a small amount perisplenic ascetic fluid (asterix). C) 65 months CT study shows thickened peritoneal metastasis in right subphrenic space with an 
increase in ascitic fluid. 
A.G. Dalgleish et al.                                                                                                                                                                                                                            
